Overview
Indian pharmaceutical industry despite being producer and supplier for approximately 20% of the World's generic drugs, has also evolved during the past decade into innovative drug development, including new chemical and biological entities, biosimilars, and innovative differentiated products.
DIA India aims to create an initiative that will address the clinical and regulatory aspects of drug development, through a comprehensive single day workshop on the latest ICH guidelines and developments relevant to India
The objective of this program is to provide a common platform for ICH trainers, regulatory authorities, academia, investigators, service providers, and the Indian biopharmaceutical industry, to deliberate upon and understand ICH guidelines and the most recent updates, impacting the drug development spectrum including key clinical, regulatory and quality aspects.
Program Committee
-
Michelle Limoli, PharmD, RPh Senior International Health Science Advisor, Office of the Director, CBER
FDA, United States -
Ramesh Jagannathan Associate Vice President – R&D
Biocon Limited, India -
Anupama Ramkumar Principal Consultant & CEO
Arkus Research, India -
Seema Pai, MD Director & Head - India Cluster
Pfizer Ltd., India -
Ashwani Pandita General Manager- Quality Management & Training Clinical Research Operations
Glenmark Pharmaceuticals Limited, India -
Prabhat Kumar Head- Pharma Quality
Accenture, India -
Sonika Shah, MSc Head - Regulatory Affairs
Amgen Technology Pvt. Ltd., India
Have an account?